From the Department of Neurology, Ningbo First Hospital, Zhejiang, China (Y.W., J.Y.).
Department of Neurology, Hangzhou First Hospital, Zhejiang University School of Medicine, China (C.Y., L.J.).
Stroke. 2018 Nov;49(11):2783-2785. doi: 10.1161/STROKEAHA.118.022919.
Background and Purpose- This study aimed to explore safety of tirofiban in endovascular treatment of acute ischemic stroke. Methods- Two hundred eighteen ischemic stroke patients receiving endovascular thrombectomy were prospectively recruited, with 94 treated with intra-arterial tirofiban and 124 were not. The 2 groups were compared in terms of symptomatic intracranial hemorrhage (ICH) and fatal ICH rate by the χ test and logistic regression. Results- Patients treated with tirofiban compared with those without tirofiban had significantly higher rate of symptomatic ICH (14.6% versus 5.7%; P=0.027) and fatal ICH (8.8% versus 1.6%; P=0.014). Tirofiban-treated patients had increased odds of symptomatic ICH by 2.9-fold (95% CI, 1.1-7.5), and odds of fatal ICH increased by 5.9-fold (95% CI, 1.2-28.4). Conclusions- Tirofiban treatment increases risk of major ICH after endovascular thrombectomy for acute ischemic stroke in this nonrandomized study.
背景与目的-本研究旨在探讨替罗非班在急性缺血性脑卒中血管内治疗中的安全性。方法-前瞻性招募了 218 例接受血管内血栓切除术治疗的缺血性脑卒中患者，其中 94 例接受了动脉内替罗非班治疗，124 例未接受治疗。采用 χ 检验和 logistic 回归比较两组症状性颅内出血（ICH）和致命性 ICH 发生率。结果-与未接受替罗非班治疗的患者相比，接受替罗非班治疗的患者症状性 ICH 发生率（14.6%对 5.7%；P=0.027）和致命性 ICH 发生率（8.8%对 1.6%；P=0.014）显著更高。替罗非班治疗患者发生症状性 ICH 的可能性增加了 2.9 倍（95%CI，1.1-7.5），发生致命性 ICH 的可能性增加了 5.9 倍（95%CI，1.2-28.4）。结论-在这项非随机研究中，替罗非班治疗增加了急性缺血性脑卒中血管内血栓切除术后发生主要 ICH 的风险。
